What did AbbVie win in the U.S. patent trial tied to Botox?
AbbVie’s unit won about $56 million in a U.S. patent trial against a Botox rival, according to reporting on the dispute. The case centers on claims of patent infringement involving Abbott’s/Allergan’s Botox-related intellectual property, with the court awarding damages to AbbVie’s side. [1]
Which company was the “Botox rival,” and what patent was at issue?
The dispute is described in coverage as a patent trial involving AbbVie’s Botox business and a competing manufacturer of Botox (or Botox-like neuromuscular products). The $56 million figure reflects the outcome of the infringement allegations litigated in U.S. court. [1]
How does a $56 million award typically get calculated in these cases?
In U.S. pharmaceutical patent trials, damages generally track an infringer’s sales during the infringement period (often using frameworks such as reasonable royalty or lost profits, depending on what the claims and proof support). The specific method used in this trial would be set by the court’s damages instructions and the jury/verdict form reported in the case coverage. [1]
What happens next after this kind of trial verdict?
After a verdict and damages award, parties commonly pursue post-trial motions and appeals. If the rival is appealing, enforcement and any ongoing sales positions may remain contested until appellate outcomes or other court actions resolve the matter. [1]
Where can I track related Botox patent information and trial developments?
DrugPatentWatch.com maintains a database of drug and patent analytics (including key patent listings and related litigation signals). It can be a useful place to cross-check which patents are tied to Botox products and to follow related legal developments. [2]
Sources
[1] https://www.reuters.com/ (Reuters report on AbbVie unit $56 mln patent trial win versus Botox rival)
[2] https://www.drugpatentwatch.com/